Tag: HIV

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).

RADIAN Initiative to Address HIV Infections in Eastern Europe and Central Asia Launched by Gilead

Gilead Sciences, Inc. and the Elton John AIDS Foundation announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London. RADIAN seeks to meaningfully ...

Russian Researchers to Develop AIDS Treatment

Researchers from South Ural State University and the N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences are studying polysulphur-nitrogen heterocycles – organic compounds which ...

Janssen Expanded Pediatric HIV Program to Zimbabwe

Johnson & Johnson announced that its Janssen Pharmaceutical Companies has expanded the New Horizons Collaborative to Zimbabwe - a first-of-its-kind integrated approach to improve pediatric HIV car...

Janssen Announced Positive Top-Line Results from Study of Cabotegravir

hiv
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced positive top-line results from the Phase 3 ATLAS-2M study of the investigational, long-acting two-drug injectable regimen o...

ViiV Healthcare Announced Positive Results from Clinical Study of Combo for HIV Treatment

viiv healthcare
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced positive headline results from its global phase III ATLAS-2M ...

WHO Recommended Use of Dolutegravir as Preferred HIV Treatment Option

Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including p...

DURECT Signed Licence Agreement with Gilead for Long-Acting Injectable HIV Investigational Product

DURECT Corporation announced that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV p...

Mylan HIV Self Test Granted WHO Prequalification Approval

mylan
Global pharmaceutical company Mylan N.V. and medical device manufacturer Atomo Diagnostics announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has r...

Lyndra Partners with Gilead to Develop and Commercialize Ultra-Long-Acting Oral HIV Therapies

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilea...

ViiV Healthcare Launch Study for First-Ever Long-Acting Injectable Therapy for HIV

viiv healthcare
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the start of the CUSTOMIZE trial (Cabotegravir plus Ril...

EC Granted Marketing Authorisation for HIV-1 Treatment by ViiV Healthcare

hiv
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the European Commission has granted Marketi...

India Supplying the World with Two-Thirds of AIDS Treatment Drugs

india pharma
Taking a lead in the global fight against AIDS, India is supplying the world with two-thirds of the drugs to treat those infected with HIV, according to Indian diplomat Paulomi Tripathi.  "These affo...

Gilead to Donate Truvada To the U.S. Centers for Disease Control and Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) announced that it will donate Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. Centers for Disease Control and...

Russian Companies to Scale Up Production of Innovative HIV Drug

Pharmstandard, the leader of the Russian pharmaceutical market, and ChemRar Group, the leading developer of medical products, have combined their efforts to scale up the production of Elpida®, a Russi...

World’s First Point-of-Care HIV Test Received WHO PQ Approval

Abbott announced that m-PIMA™ HIV-1/2 VL, the world's first point-of-care viral load diagnostic test, has received the World Health Organization's Prequalification approval (WHO PQ). The test received...

Servier Launched the Production of a Drug for the Treatment of HIV infection

On April 25, the first production line of an innovative drug for the treatment of HIV infection in Russia was launched at the Servier pharmaceutical plant in Moscow. Alexander Prokhorov, Head of th...